The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers.
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Muralidhar Beeram
No Relationships to Disclose
 
Mariela A. Blum
No Relationships to Disclose
 
Diana Felice Hausman
Employment - Zymeworks
Leadership - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - TaiRx, Inc.
Research Funding - Aeglea Biotherapeutics (Inst); Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst)
 
Gerry Rowse
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Jamuna Thimmarayappa
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst)
 
Erika Paige Hamilton
Consulting or Advisory Role - Cascadian Therapeutics (Inst); Flatiron Health; Genentech/Roche (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Cascadian Therapeutics (Inst); Curis (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Kadmon (Inst); Lilly (Inst); Lycera (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Verastem (Inst); Zymeworks (Inst)